AtriCure (ATRC) Competitors $38.47 +0.83 (+2.21%) As of 01/17/2025 04:00 PM Eastern Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends ATRC vs. ITGR, IART, ATEC, OFIX, SRDX, ANGO, ARAY, RMTI, RSLS, and ABTShould you be buying AtriCure stock or one of its competitors? The main competitors of AtriCure include Integer (ITGR), Integra LifeSciences (IART), Alphatec (ATEC), Orthofix Medical (OFIX), Surmodics (SRDX), AngioDynamics (ANGO), Accuray (ARAY), Rockwell Medical (RMTI), ReShape Lifesciences (RSLS), and Abbott Laboratories (ABT). These companies are all part of the "health care equipment" industry. AtriCure vs. Integer Integra LifeSciences Alphatec Orthofix Medical Surmodics AngioDynamics Accuray Rockwell Medical ReShape Lifesciences Abbott Laboratories Integer (NYSE:ITGR) and AtriCure (NASDAQ:ATRC) are both medical companies, but which is the better business? We will compare the two businesses based on the strength of their earnings, community ranking, analyst recommendations, media sentiment, dividends, risk, valuation, profitability and institutional ownership. Do institutionals & insiders hold more shares of ITGR or ATRC? 99.3% of Integer shares are owned by institutional investors. Comparatively, 99.1% of AtriCure shares are owned by institutional investors. 2.0% of Integer shares are owned by insiders. Comparatively, 3.2% of AtriCure shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term. Do analysts rate ITGR or ATRC? Integer currently has a consensus price target of $145.44, suggesting a potential upside of 3.22%. AtriCure has a consensus price target of $42.00, suggesting a potential upside of 9.18%. Given AtriCure's stronger consensus rating and higher possible upside, analysts clearly believe AtriCure is more favorable than Integer.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Integer 0 Sell rating(s) 1 Hold rating(s) 8 Buy rating(s) 0 Strong Buy rating(s) 2.89AtriCure 0 Sell rating(s) 0 Hold rating(s) 8 Buy rating(s) 0 Strong Buy rating(s) 3.00 Does the MarketBeat Community believe in ITGR or ATRC? AtriCure received 173 more outperform votes than Integer when rated by MarketBeat users. Likewise, 69.17% of users gave AtriCure an outperform vote while only 63.92% of users gave Integer an outperform vote. CompanyUnderperformOutperformIntegerOutperform Votes38863.92% Underperform Votes21936.08% AtriCureOutperform Votes56169.17% Underperform Votes25030.83% Which has more risk & volatility, ITGR or ATRC? Integer has a beta of 1.12, meaning that its stock price is 12% more volatile than the S&P 500. Comparatively, AtriCure has a beta of 1.42, meaning that its stock price is 42% more volatile than the S&P 500. Is ITGR or ATRC more profitable? Integer has a net margin of 6.70% compared to AtriCure's net margin of -8.70%. Integer's return on equity of 11.63% beat AtriCure's return on equity.Company Net Margins Return on Equity Return on Assets Integer6.70% 11.63% 5.86% AtriCure -8.70%-8.12%-6.21% Does the media refer more to ITGR or ATRC? In the previous week, AtriCure had 15 more articles in the media than Integer. MarketBeat recorded 16 mentions for AtriCure and 1 mentions for Integer. Integer's average media sentiment score of 0.76 beat AtriCure's score of 0.46 indicating that Integer is being referred to more favorably in the media. Company Overall Sentiment Integer Positive AtriCure Neutral Which has preferable earnings & valuation, ITGR or ATRC? Integer has higher revenue and earnings than AtriCure. AtriCure is trading at a lower price-to-earnings ratio than Integer, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioInteger$1.60B2.96$90.65M$3.2443.49AtriCure$399.24M4.70-$30.44M-$0.83-46.35 SummaryInteger beats AtriCure on 9 of the 17 factors compared between the two stocks. Get AtriCure News Delivered to You Automatically Sign up to receive the latest news and ratings for ATRC and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ATRC vs. The Competition Export to ExcelMetricAtriCureSurgical & medical instruments IndustryMedical SectorNASDAQ ExchangeMarket Cap$1.53B$4.51B$5.22B$8.94BDividend YieldN/A47.30%5.13%4.04%P/E Ratio-46.3526.2989.7217.34Price / Sales4.7058.321,251.2178.56Price / CashN/A50.1443.8235.97Price / Book3.917.795.324.79Net Income-$30.44M$13.87M$122.69M$225.00M7 Day Performance22.48%1.46%-0.16%1.52%1 Month Performance27.17%11.95%3.75%4.68%1 Year Performance16.58%53.01%27.41%20.89% AtriCure Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ATRCAtriCure1.9181 of 5 stars$38.47+2.2%$42.00+9.2%+15.1%$1.53B$399.24M-46.351,200High Trading VolumeITGRInteger2.7648 of 5 stars$134.84+0.8%$145.44+7.9%+35.5%$4.52B$1.71B41.6210,500IARTIntegra LifeSciences3.5318 of 5 stars$22.30+2.2%$23.00+3.1%-42.5%$1.72B$1.56B-247.753,946Short Interest ↓ATECAlphatec4.4361 of 5 stars$10.95+9.8%$17.44+59.3%-23.4%$1.55B$572.74M-8.55700Analyst ForecastInsider TradeHigh Trading VolumeOFIXOrthofix Medical2.7242 of 5 stars$17.29+1.7%$23.00+33.0%+36.3%$660.72M$784.25M-5.521,090Insider TradeNews CoverageSRDXSurmodics4.2277 of 5 stars$36.02-6.3%$50.00+38.8%+10.3%$514.87M$126.08M-44.47450Analyst ForecastNews CoverageANGOAngioDynamics4.0079 of 5 stars$12.47+1.4%$13.00+4.3%+111.0%$506.71M$292.73M-2.05760Short Interest ↓News CoverageGap DownARAYAccuray4.4617 of 5 stars$2.20+2.8%$9.00+309.1%-19.4%$221.24M$444.20M-12.941,040Short Interest ↑RMTIRockwell Medical4.3251 of 5 stars$2.04-1.9%$6.00+194.1%+47.2%$65.93M$98.92M-40.80300Short Interest ↓News CoveragePositive NewsRSLSReShape Lifesciences1.1526 of 5 stars$5.11+13.6%N/A-65.5%$3.64M$8.18M0.0050Short Interest ↓Positive NewsGap UpHigh Trading VolumeABTAbbott Laboratories4.7556 of 5 stars$112.98+0.6%$131.57+16.5%-0.4%$195.96B$41.22B34.34115,000Options VolumeNews Coverage Related Companies and Tools Related Companies ITGR Competitors IART Competitors ATEC Competitors OFIX Competitors SRDX Competitors ANGO Competitors ARAY Competitors RMTI Competitors RSLS Competitors ABT Competitors Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:ATRC) was last updated on 1/18/2025 by MarketBeat.com Staff From Our PartnersLast time you’ll see this priced at $1.00When was the last time you bought something for a buck? I don’t even think you can buy anything at McDonalds f...StocksToTrade | SponsoredThe Biggest Money-Making Idea in My 43 Years in the Stock MarketBillionaires and top investors - including the late great Charlie Munger - and many more names you would recog...The Oxford Club | SponsoredWe recommended Palantir in 2021, now we’re recommending this...I believe it could offer you a MAJOR boost to your retirement. And it pays huge dividends to give you a nic...Behind the Markets | SponsoredGrab This Altcoin Before Trump's Crypto AnnouncementThe #1 Coin Poised to Soar Under Trump Pro-Crypto White House could make this the investment opportunity of...Crypto 101 Media | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredStunning Trump Exec Order LeakedThis secret document contains stunning details about Donald Trump’s very first order of business… the minute h...Banyan Hill Publishing | SponsoredThe #1 Crypto for AIWe’ve issued an urgent landmark trade alert for a new crypto wonder. So, I decided to give you this heads-u...Weiss Ratings | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowAltcoin season moves fast, and those who hesitate are left behind. The window is closing.Crypto Swap Profits | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding AtriCure, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share AtriCure With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.